Results 221 to 230 of about 19,420 (250)
Some of the next articles are maybe not open access.
Nicotine & Tobacco Research, 2023
INTRODUCTION A smoking-cessation program was implemented as a randomized non-inferiority trial in primary care practices in Croatia and Slovenia to investigate whether a standard 4-week treatment with cytisine was at least as effective and feasible as a ...
T. Oreskovic +6 more
semanticscholar +1 more source
INTRODUCTION A smoking-cessation program was implemented as a randomized non-inferiority trial in primary care practices in Croatia and Slovenia to investigate whether a standard 4-week treatment with cytisine was at least as effective and feasible as a ...
T. Oreskovic +6 more
semanticscholar +1 more source
Int. Journal of Clinical Pharmacology and Therapeutics, 2020
Varenicline is an effective drug for smoking cessation. The aim of the present study was to compare the pharmacokinetics and safety profiles of two different varenicline formulations (varenicline tartrate (reference) and varenicline oxalate (test)), each containing 1 mg varenicline base in humans.A randomized, open-label, two-sequence, two-period ...
Jin-Woo Park +4 more
openaire +3 more sources
Varenicline is an effective drug for smoking cessation. The aim of the present study was to compare the pharmacokinetics and safety profiles of two different varenicline formulations (varenicline tartrate (reference) and varenicline oxalate (test)), each containing 1 mg varenicline base in humans.A randomized, open-label, two-sequence, two-period ...
Jin-Woo Park +4 more
openaire +3 more sources
Intranasal Varenicline: Review of a Novel Formulation for the Treatment of Dry Eye Disease
Journal of pharmacy and practice, 2022Objective: To examine the literature pertaining to safety and efficacy of intranasal (IN) varenicline for the treatment of dry eye disease (DED). Data Sources: A literature search of PubMed was performed (1985 to January 2022) using the following search ...
K. Zitko, Lauren Ladd, T. Dougherty
semanticscholar +1 more source
Alcoholism: Clinical and Experimental Research, 2022
BACKGROUND The U.S. Food and Drug Administration identifies abstinence and the absence of heavy drinking days as outcomes for pharmacotherapy trials for alcohol use disorder (AUD).
Steven J. Nieto +4 more
semanticscholar +1 more source
BACKGROUND The U.S. Food and Drug Administration identifies abstinence and the absence of heavy drinking days as outcomes for pharmacotherapy trials for alcohol use disorder (AUD).
Steven J. Nieto +4 more
semanticscholar +1 more source
2012
Varenicline is a novel agent that is centrally acting partial nicotinic acetylcholine receptor antagonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action,better efficacy and tolerability
Mohammed Gabr Kassem +1 more
openaire +3 more sources
Varenicline is a novel agent that is centrally acting partial nicotinic acetylcholine receptor antagonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action,better efficacy and tolerability
Mohammed Gabr Kassem +1 more
openaire +3 more sources
Nicotine & Tobacco Research, 2021
INTRODUCTION Varenicline and combination nicotine replacement treatment (cNRT) have been recommended as the most effective pharmacotherapies, with equal abstinence rate for smoking cessation in a network meta-analysis of randomized trials, but data from ...
K. Hsueh, P. Tang, H. McRobbie
semanticscholar +1 more source
INTRODUCTION Varenicline and combination nicotine replacement treatment (cNRT) have been recommended as the most effective pharmacotherapies, with equal abstinence rate for smoking cessation in a network meta-analysis of randomized trials, but data from ...
K. Hsueh, P. Tang, H. McRobbie
semanticscholar +1 more source
Varenicline Prevents SARS-CoV-2 Infection In Vitro and in Rhesus Macaques
bioRxiv, 2021Background SARS-CoV-2 infections have resulted in a global pandemic, but an antiviral therapy for this novel strain of coronavirus does not currently exist.
J. Nau +5 more
semanticscholar +1 more source
Varenicline for the Treatment of Cocaine Dependence
Journal of Addiction Medicine, 2021Objectives: Varenicline is a partial agonist at the α2β4 and α6β2 nAChR receptors and a full agonist at α7 receptors. Both α7 and α6β2 receptors are implicated in the neural reward circuitry activated by cocaine use. A preliminary clinical trial suggested that varenicline treatment reduced cocaine use.
Mila Tamminga +6 more
openaire +3 more sources
Journal of the American Medical Association (JAMA)
Importance Most people who smoke do not quit on their initial attempt. Objective To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT). Design, Setting,
P. Cinciripini +11 more
semanticscholar +1 more source
Importance Most people who smoke do not quit on their initial attempt. Objective To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT). Design, Setting,
P. Cinciripini +11 more
semanticscholar +1 more source
Nicotine & Tobacco Research, 2021
INTRODUCTION In the general population, varenicline is consistently shown to be more efficacious for smoking cessation than nicotine replacement therapy (NRT).
S. Choi +7 more
semanticscholar +1 more source
INTRODUCTION In the general population, varenicline is consistently shown to be more efficacious for smoking cessation than nicotine replacement therapy (NRT).
S. Choi +7 more
semanticscholar +1 more source